reason report
bottom line reiter op follow solid
sales/ep higher estim highlight quarter includ
procedur growth out-performance vs street reflect
y/i acceler improv q/q system asp especi focu given last
margin upsid result healthi ep growth acceler
qtr vs see growth momentum estimate upsid
potenti sustain out-year new product cycl continu
unfold compani drive increas penetration/accept
grow set int market new us gen surgeri procedur area
 ahead expect margin outperform
report revenue vs consensu system revenue
came expect vs consensu driven
lower-than-project placement oper leas
in-qtr revenue vs street model instrument accessori
procedur revenue slightli ahead street expect vs
consensu servic revenue came line
consensu gm beat consensu
us adj ebita mgn vs consensu
svbl opex came lower expect primarili sg
incom in-lin think lower share count
vs model result ep ultim beat our/street
medic suppli devic
dcf wgtd average cost
net debt total capit
price-to-earnings lt ep growth
compani inform svb leerink llc research
revenu mm ep ex item stock expens defer revenu amort
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
ww procedur growth exclud headwind time
ou beat consensu in-lin us
growth adj effect math
bigger sourc upsid vs consensu qtr part driven re-
acceler china capac expans posit impact
region growth profil faster would expect
new system place far start qtr new quota
bullish sign view us procedur growth y/i
in-lin think reflect y/i acceler vs strong us
gen surgeri momentum estimate growth thorac continu
overpow expect slow trend matur us procedur like
urology/gyn trend lsd-msd rang management
rais low end procedur guidanc vs prior
continu believ like prove
conserv given on-going momentum us gen surgeri japan
capac expans come heel recent approv
china quota expans procedur growth forecast
within us gen surgeri management call still solid though slightli
slower growth trend vs hernia colon resect
off-set increas contribut growth
slow hernia colorect growth function
institut bump access issu time robot
view high level problem solvabl
system placement come much surpris
us heard feedback convers hernia
bariatr surgeon beforethat robot access/tim issu dv
adopt rate would like even higher across multipl gen surgeri
area includ hernia commentari around bariatr support
view emerg categori could near inflect point
vs con compris us system vs ou vs
mix toward higher cost xi drove system asp
system qtr da vinci xi vs da
vinci system vs continu place system
financ altern op leas usage-bas
arrang repres lower total system placement
qtr collect compris ww/u placement
vs
ww higher come vs last qtr due
higher higher cost system low mix distributor vs direct sale
fewer multi-system arrang less volum discount
go-forward basi management expect asp trend average
low point high point
slightli lower percentag op leas multi-system deal
qtr expect bounc around long run
type placement benefici move physician
across hospit definit da vinci camp ahead
new entrant look enter robot marketplac sever
year multipl new platform come downsid
variabl nt revenu saw downsid
saw upsid benefit long run far outweigh view
initi allow expand footprint acceler
pace especi front potenti competit come
time-frame turn enhanc potenti out-year procedur growth
upsid op leas model time also mean smoother
predict capit revenu stream meanwhil higher proport
trade-in multi-system deal essenti repres custom opt
year price history/av daili volume mil
upgrad portfolio standard lead stickier
custom entrench da vinci ecosystem
ww procedur growth estimate upper end management
rang ep goe vs
rate share outperform ultim believ key valu driver
place stock work intermediate-to-longer-term acceler
procedur growth new product cycl momentum continu uniqu robot
colorect bariatr thorac head neck other acceler growth procedur
adopt intern dvp da vinci prostatectomi europ japan addtl procedur
reimburs china new quota new product cycl xi sp ion help
sustain above-averag top- bottom-lin double-digit growth system advanc
continu open increment surgery/revenu sourc time shape
invest year origin anticip surpris management
want dial reinvest time two back-to-back new product cycl sp
 flex cathet robot line sight multipl lt develop opportun
expans china india informatics/ai surgeri initi expect stepped-up
invest ultim enhanc market leadership posit expand surgic
robot categori potenti increas payoff out-year also continu
believ sustain uniqu large-cap med-tech mid-teen revenue growth least profil
complement mid-teen better ep growth compound-annual-growth-rate
valuat base dcf analysi yield pt discount rate
calcul use capm model current trade price-to-earnings ex-cash
basi incl cash ex-cash incl cash vs broader market
cap med-tech average incl ew pt
impli appli adj ep less int incom cash believ
isrg premium group sustain given above-averag top- bottom-
line growth compound-annual-growth-rate potenti vs peer amid multipl new product cycl help drive
increas penetr still-larg under-penetrated long-term robot surgeri opportun
risk valuat includ high volatil wide-trad rang stock
compani relianc singl product robot potenti chang wors hospit
capit spend environ continu debat around cost/benefit come
adopt robot procedur current project valuat could risk
gyn/uro trend slow greater degre model newer gener surgeri robot
procedur slower expect adopt forecast anticipated-to-launch
nexgen sp platform delay fail gain traction launch compani cant
achiev revenu contribut model flexibl cathet robot program
key risk includ ou growth slower anticip -- -either due delay
develop new japan procedur opportun and/or new china system tender/quota
newer robot entrant mdt/jnj beyond come onto
scene result competit trial potenti caus hospit purchas cycl elong
given robot solut evalu sg invest combat competit
develop new market lead greater opex spend -- -potenti limit near-term
earn power -- -v weve model
dollar million except ep
compani report svb leerink llc estim
dollar million except ep
compani report svb leerink llc estim
higher end
compani report svb leerink llc estim
dollar million except per share data
good sold ex-amort/sbc/def cog
disc op debt ext /recap net tax
pre-split dilut averag share million
post-split dilut averag share million
compani report svb leerink llc estim
dollar million except per share data
total
revenu mix sale
compani report svb leerink llc estim
